Critical considerations into the new EMA guideline on bioequivalence

 

 Buy Article Permissions and Reprints

Abstract

The market of generic drugs has been greatly developing during the last 15 years in various European Union (EU) member states, mainly in the Mediterranean area, including non-EU countries, i. e. in the Middle East. This has required a more detailed support from EMA (European Medicines Agency) as guidelines are concerned. Previous EU guidelines on bioavailability and bioequivalence neglected some relevant issues often met in bioequivalence trials, defined in the literature as “open questions on bioequivalence”. In the absence of EU specific directives these problems were managed by EU investigators in compliance with US FDA (Food and Drug Administration) guidelines that had already considered some of these “open problems”.

The latest EMA guideline operating from August 1, 2010 focuses on various relevant issues, including directions on orodispersible tablets, how to operate in the case of high variability, or how to manage the carryover effect of plasma concentrations, but, e. g., it is still neglecting the issue of the multiple-peak phenomenon. In addition, comprehensive directions are still needed on how to manage clinical studies in which endogenous substances are involved.

The present review focuses on situations now appropriately discussed in the latest EU guideline, as well as other situations that still need to be defined and need further attention by the regulatory agency in order to give additional adequate directions to the investigators.

• References

• 1 Note for guidance: Investigation of bioavailability and bioequivalence. Commission of European Communities, III/54/89-EN Final. December 1991.
  PubMedGoogle Scholar
• 2 Note for guidance on the investigation of bioavailability and bioequivalence. EMEA, CPMP/EWP/QWP/1401/98. July 26, 2001.
  PubMedGoogle Scholar
• 3 Questions and answers on the bioavailability and bioequivalence guideline. EMEA, CHMP/EWP/40326/2006.
  PubMedGoogle Scholar
• 4 Questions and answers: positions on specific questions addressed to the EWP therapeutic subgroup on pharmacokinetics. EMEA, 618604/2008 Rev. 1, July 23, 2009.
  PubMedGoogle Scholar
• 5 Guideline on the investigation on bioequivalence. EMEA, CPMP/QWP/EWP/1401/98 Rev. 1. January 20, 2010.
  PubMedGoogle Scholar
• 6 Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents. CPMP/EWP/239/95.
  PubMedGoogle Scholar
• 7 Note for guidance: replacement of chlorofluorocarbons (CFCs) in metered dose inhalation products. CPMP/III/5378/93-Final.
  PubMedGoogle Scholar
• 8 Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD). CPMP/EWP/4151/00 Rev 1.
  PubMedGoogle Scholar
• 9 Guideline on the pharmaceutical quality of inhalation and nasal products. EMEA, CHMP/QWP/49313/2005Corr.
  PubMedGoogle Scholar
• 10 Guideline on the clinical development of fixed combination medicinal products. CPMP/EWP/240/95 Rev. 1.
  PubMedGoogle Scholar
• 11 Note for guidance on modified release oral and transdermal dosage forms: section II. CPMP/EWP/280/96Corr.
  PubMedGoogle Scholar
• 12 Guidance for industry: bioavailability and bioequivalence. Studies for orally administered drug products. General considerations. U.S. Department of Health and Human Services, FDA, CDER; March 2003, Revision 1.
  PubMedGoogle Scholar
• 13 Guidance for industry: in vivo bioequivalence studies based on population and individual bioequivalence approaches. U.S. Department of Health and Human Services, FDA, CDER; October 1997 BPX.
  PubMed
• 14 Guidance: oral extended (controlled) release dosage forms: in vivo bioequivalence and in vitro dissolution testing. Dighe SV, Williams RL, editors. FDA; September 1993.
  PubMed
• 15 Guidance for industry: Extended release oral dosage forms: development, evaluation, and application of in vitro I in vivo correlations. U.S. Department of Health and Human Services, FDA, CDER; September 1997.
  PubMed
• 16 Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. U.S. Department of Health and Human Services, FDA, CDER; December 2002 BP.
  PubMed
• 17 Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on a biopharmaceutics classification system. U.S. Department of Health and Human Services, FDA, CDER; January 1999 BP.
  PubMedGoogle Scholar
• 18 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scriptslcderlobldefault.cfm Accessed: Sep 2010.
  PubMed
• 19 Diletti E, Hauschke D, Steinijans VW. Sample size determinations: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Clin Pharmacol Ther Toxicol. 1992; 30: S59-62
  PubMedGoogle Scholar
• 20 Marzo A, Fontana E. How improved sensitivity of bioas-says, and terminal half-life of drugs impact on bioequivalence trials. Arzneimittelforschung. 2009; 59: 55-8
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Louning PE, Lien EA, Lundgren S, Kvimsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet. 1992; 22: 327-58
  CrossrefPubMedGoogle Scholar
• 22 Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet. 1994; 26: 7-15
  CrossrefPubMedGoogle Scholar
• 23 Marzo A. Crossover design in tamoxifen bioequivalence: a borderline situation. JPharm Pharmacol. 1998; 50: 1433-4
  PubMedGoogle Scholar
• 24 Marzo A. Open questions on bioequivalence: some problems and some solutions. Pharmacol Res. 1999; 40: 357-68
  CrossrefPubMedGoogle Scholar
• 25 Marzo A. Bioequivalence behind the scenes. Parm Dev Regal. 2003; 1: 179-89
  PubMedGoogle Scholar
• 26 Rusca A, Di Stefano AF, Doig MV, Scarsi C, Perucca E. Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol. 2009; 65: 503-10
  CrossrefPubMedGoogle Scholar
• 27 Marzo A, Fibbioli M, Marone C, Cerutti B. The degree of predictivity in pilot studies on six subjects in bioequivalence trials. Pharmacol Res. 2004; 49: 283-6
  CrossrefPubMedGoogle Scholar
• 28 Marzo A. Open questions on bioequivalence: an updated reappraisal. Curr Clin Pharmacol. 2007; 2: 179-89
  CrossrefPubMedGoogle Scholar
• 29 Fourtillan JB, Bubourg D. Etude pharmacocinetique du Piroxicam chez l'homme sain, apres administration d'une dose egale à 20 mg par voie orale. Therapie. 1983; 38: 163-70 French.
  PubMedGoogle Scholar
• 30 Brogden RN, Heel RC, Speight TM, Avery GS. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs. 1984; 28: 292-323
  CrossrefPubMedGoogle Scholar
• 31 Marzo A, Reiner V. Open questions on bioequivalence: the case of multiple peak phenomenon. J Pharm Pharmacol. 2004; 56: 281-2
  CrossrefPubMedGoogle Scholar
• 32 Reiner V, Reiner A, Reiner G, Conti M. Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt. Arzneimittelforschung. 2001; 51: 885-90
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 Chan KH, Mojaverian P, Ziehmer BA, John VA. Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers. Pharm Res. 1990; 7: 1026-32
  CrossrefPubMedGoogle Scholar
• 34 Terhaag B, Gramatte T, Hrdlcka P, Richter K, Feller K. The influence of food on the absorption of diclofenac as a pure substance. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 418-21
  PubMedGoogle Scholar
• 35 Marià MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther. 1995; 33: 333-9
  PubMedGoogle Scholar
• 36 Bettini R, Giordano F, Donini C, Massimo G, Castellani PL, Colombo P. Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets. STP Pharma Sci. 2000; 10: 335-9
  PubMedGoogle Scholar
• 37 Idegami H, Shima K, Tanaka A, Tahara Y, Hirota M, Kumahara Y. Interindividual variation in the absorption of glibenclamide in man. Acta Endocrinol. 1986; 111: 528-32
  PubMedGoogle Scholar
• 38 Balan G, Timmins P, Greene DS, Marathe PH. In-vitro in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers. J Pharm Pharmacol. 2000; 52: 831-8
  CrossrefPubMedGoogle Scholar
• 39 Parquet M, Metman EH, Raizman A, Rambaud JC, Berthaux N. Bioavailability, gastrointerstinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man. Eur J Clin Invest. 1985; 15: 171-8
  CrossrefPubMedGoogle Scholar
• 40 Najib NM, Idkaidek N, Adel A, Admour I, Astigarraga REB, De Nucci G et al. Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm Drug Dis-pos. 2003; 24: 183-9
  CrossrefPubMedGoogle Scholar
• 41 Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Clin Pharmacokinet. 1991; 20: 218-36
  CrossrefPubMedGoogle Scholar
• 42 Grannén A, VanBahr C, Lindström B, Rosen A. Bioavailability and pharmacokinetics of Cimetidine. Eur J Clin Pharmacol. 1979; 16: 335-40
  CrossrefPubMedGoogle Scholar
• 43 Somogyi A, Gugler R. Clinical pharmacokinetics of Cimetidine. Clin Pharmacokinet. 1983; 8: 463-95
  CrossrefPubMedGoogle Scholar
• 44 Marzo A. Toxicokinetics of endogenous substances: a neglected issue. Arzneimittelforschung. 1996; 46: 1-10
  PubMed
• 45 Marzo A, Rescigno A. Pharmacokinetics of endogenous substances: some problems and some solutions. Eur J Drug Metab Pharmacokinet. 1993; 18: 77-88
  CrossrefPubMedGoogle Scholar
• 46 Marzo A, Rescigno A, Arrigoni Martelli E. Some pharmacokinetic considerations about homeostatic equilibrium of endogenous substances. Eur J Drug Metab Pharmacokinet. 1993; 18: 215-9
  CrossrefPubMedGoogle Scholar
• 47 Marzo A, Vuksic D, Crivelli F. Bioequivalence of endogenous substances facing homeostatic equilibria: an example with potassium. Pharmacol Res. 2000; 42: 523-5
  CrossrefPubMedGoogle Scholar
• 48 Guidance for industry: potassium chloride modified-re-lease tablets and capsules: in vivo bioequivalence and in vitro dissolution testing. U.S. Department of Health and Human Services, CDER; October 2005.
  PubMed
• 49 Levothyroxine sodium tablets. In vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. US FDA 3/8/2001.
  PubMed
• 50 De Vito JM, Kozloski GD, Tonelli AP, Johreson JB. Bioequivalence of oral and injectable levoleucovorin and leucovor-in. Clin Pharm. 1993; 12: 293-9
  PubMedGoogle Scholar
• 51 Rennie D. Thyroid storm. JAm Med Assoc. 1997; 277: 1238-43
  PubMedGoogle Scholar
• 52 Spigelmaw MK. Bioequivalence of levothyroxine preparations for treatment of hypothyroidism. J Am Med Assoc. 1997; 277: 1199-200
  CrossrefPubMedGoogle Scholar
• 53 Eckert CH. Bioequivalence of levothyroxine preparations: industry sponsorship and academic freedom. J Am Med Assoc. 1997; 277: 1200-1
  CrossrefPubMedGoogle Scholar
• 54 Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. J Am Med Assoc. 1997; 277: 1205-13
  CrossrefPubMedGoogle Scholar
• 55 Cerutti R, Rivolta G, Cavalieri L, Di Giulio C, Grossi E, Vago T et al. Bioequivalence of levothyroxine tablets administered in target population in steady state. Pharmacol Res. 1999; 39: 193-201
  CrossrefPubMedGoogle Scholar
• 56 Murphy BEP. Some studies of the protein-binding of steroids and their application to the routine micro- and ultra-micro measurement of various steroids in body fluids by competitive protein binding-assay. J Clin Endocrinol Me-tab. 1967; 27: 973-90
  CrossrefPubMedGoogle Scholar
• 57 Scotti A, Bianchini C, Abbiati G, Marzo A. Absorption of calcium administered alone or in fixed combination with vitamin D to healthy volunteers. Arzneimittelforschung. 2001; 51: 493-500
  Article in Thieme ConnectPubMedGoogle Scholar
• 58 Chen XY, Zhong DF, Duan JL, Yan BX. LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers. Xenobiotica. 2003; 33: 1261-71
  CrossrefPubMedGoogle Scholar
• 59 Murrel GAC, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986; 11: 343-53
  CrossrefPubMedGoogle Scholar
• 60 Latini R, Rognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984; 9: 136-56
  CrossrefPubMedGoogle Scholar
• 61 Marzo A, Balant LP. Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantiose-lective analytical methods. J Chromatogr B. 1996; 678: 73-92
  PubMedGoogle Scholar
• 62 Marzo P, Scaglione F. Antiplatelet and other non-antiin-flammatory activities of acetylsalicylic acid: mechanisms of action, expectations and therapeutic relevance. Intern Med. 2000; 8: 1-4
  PubMedGoogle Scholar
• 63 Bechgaard E, Nielsen A. Bioavailability of bromhexine tablets and preliminary pharmacokinetics in humans. Bio-pharm Drug Dispos. 1982; 3: 377-44
  PubMedGoogle Scholar
• 64 Findlay JWA, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol. 1981; 21: 127-35
  CrossrefPubMedGoogle Scholar
• 65 Busto U, Bendayan R, Sellers EM. Clinical Pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet. 1989; 16: 1-26
  PubMedGoogle Scholar
• 66 Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbama-zepine-10,ll-epoxide. An update. Clin Pharmaokinet. 1986; 11: 177-98
  PubMedGoogle Scholar
• 67 Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM. Clinical pharmacokinetics of chlordiazepoxide. Clin Pharmacokinet. 1978; 3: 381-94
  CrossrefPubMedGoogle Scholar
• 68 Dahl SG, Strandjord RE. Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther. 1977; 21: 437-48
  PubMedGoogle Scholar
• 69 Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993; 25: 189-204
  CrossrefPubMedGoogle Scholar
• 70 Quiding H, Anderson P, Bandesson U, Borens LO, Hynning PA. Plasma concentration of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol. 1986; 30: 673-7
  CrossrefPubMedGoogle Scholar
• 71 Greenblatt DJ, Allen MD, Harmatz JS, Shader RI. Diazepam disposition determinants. Clin Pharmacol Ther. 1980; 27: 301-12
  CrossrefPubMedGoogle Scholar
• 72 Rovei V, Gomeni R, Mitchard M, Lazzibaud J, Blatrix Ch, Thebauld JJ et al. Pharmacokinetics and metabolism of diltiazem in man. Acta Cardiol. 1980; XXV: 35-45
  PubMedGoogle Scholar
• 73 Faulkner RD, Pitts WM, Lee CS, Lewis WA, Fann WE. Multiple-dose doxepin kinetics in depressed patients. Clin Pharmacol Ther. 1983; 34: 509-15
  CrossrefPubMedGoogle Scholar
• 74 Keller T, Cambon N, Genevray M, Crivelli F, Crivelli M, Dal Bo L et al. Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. Arzneimittelforschung. 2005; 55: 491-7
  Article in Thieme ConnectPubMedGoogle Scholar
• 75 Greenblatt DJ, Divoll M, Harmatz JS, MacLaughlin DS, Shader RI. Kinetics and clinical effects of flurazepam in young and elderly non insomniacs. Clin Pharmacol Ther. 1981; 30: 475-86
  CrossrefPubMedGoogle Scholar
• 76 Radwanski E, Perentesis G, Symchowicz S, Zampaglione N. Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J Clin Pharmacol. 1989; 29: 554-8
  PubMedGoogle Scholar
• 77 Sallee FR, Pollock BG. Clinical pharmacokinetics of Imipramine and desipramine. Clin Pharmacokinet. 1990; 18: 346-64
  CrossrefPubMedGoogle Scholar
• 78 Marzo A, Treffner E. Gas-liquid chromatographic determination of isosorbide-5-mononitrate derivatized with perfluorinated anhydrides for pharmacokinetic and bioavailability investigations. J Chromatogr. 1985; 345: 390-5
  CrossrefPubMedGoogle Scholar
• 79 Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol. 1989; 28: 61-9
  CrossrefPubMedGoogle Scholar
• 80 Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990; 47: 12-9
  CrossrefPubMedGoogle Scholar
• 81 Bernareggi A. The pharmacokinetic profile of nimesulide in healthy volunteers. Drugs. 1993; 46 (Suppl 1) 64-72
  CrossrefPubMedGoogle Scholar
• 82 Thadani U, Whitsett T. Relationship of pharmacokinetic and pharmacolodynamic properties of the organic nitrates. Clin Pharmacokinet. 1988; 15: 32-43
  CrossrefPubMedGoogle Scholar
• 83 Hughes KM, Lang JCT, Lazare R, Gordon D, Stanton SL, Malone-Lee J et al. Measurement of oxybutynin and its N-desethylmetabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica. 1992; 22: 859-69
  CrossrefPubMedGoogle Scholar
• 84 Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet. 1983; 8: 297-331
  CrossrefPubMedGoogle Scholar
• 85 Martindale. The complete drug reference. 13th ed. Sweetman SC. editor. London Pharmaceutical Press 2007. p. 1250-1251
  Google Scholar
• 86 Krause W, Karras J, Seifert W. Pharmacokinetic of canre-none after oral administration of spironolactone and intravenous injection of canrenoate-k in healthy man. Eur J Clin Pharmacol. 1983; 25: 449-53
  CrossrefPubMedGoogle Scholar
• 87 McTavish D, Sorkin EM. Verapamil: an updated review of its phamadynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs. 1989; 38: 19-76
  CrossrefPubMedGoogle Scholar
• 88 Holick MF. The cutaneous photosynthesis of previtamin D3: a unique photoendocrine system. J Invest Dermatol. 1981; 77: 51-8
  CrossrefPubMedGoogle Scholar
• 89 Dal Bo L, Mazzucchelli P, Marzo A. Assay of zofenopril and its active metabolite zofenoprilat by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B. 2000; 749: 287-94
  PubMedGoogle Scholar
• 90 Marzo A, Dal Bo L, Mazzucchelli P, Ceppi Monti N, Crivelli F, Ismaili S et al. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzneimittelforschung. 2002; 52: 233-42
  Article in Thieme ConnectPubMedGoogle Scholar
• 91 Thadani U, Whitsett T. Relationship of pharmacokinetic and pharmacodynamic properties of organic nitrates. Clin Pharmacokinet. 1988; 15: 32-43
  CrossrefPubMedGoogle Scholar
• 92 Schulz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol. 1988; 34: 633-6
  CrossrefPubMedGoogle Scholar
• 93 Walter-Sack I, de Vries JX, Kreiner C, Ittensohn A, Stenzhorn G, Voss A et al Bioequivalence of allopurinol preparations: to be assayed by parent drug or the active metabolite?. Clin Invest. 1993; 71: 240-6
  PubMedGoogle Scholar
• 94 Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung. 1982; 32: 1185-90
  PubMedGoogle Scholar
• 95 White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985; 10: 187-215
  CrossrefPubMedGoogle Scholar
• 96 Mooradian AD. Digitalis: an update of clinical pharmacokinetics, therapeutic monitoring techniques, and treatment recommendations. Clin Pharmacokinet. 1988; 15: 165-79
  CrossrefPubMedGoogle Scholar
• 97 Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet. 1990; 19: 264-79
  CrossrefPubMedGoogle Scholar
• 98 Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994; 26: 201-14
  CrossrefPubMedGoogle Scholar
• 99 Bennett WM, Pulliam JP. Cyclosporine nephrotoxicity. Ann Intern Med. 1983; 99: 851-4
  PubMedGoogle Scholar
• 100 Jacobo E, Schmidt JD, Weinstein SH, Flocks RH. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology. 1976; 8: 213-33
  PubMedGoogle Scholar
• 101 Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990; 47: 12-9
  CrossrefPubMedGoogle Scholar
• 102 Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic/pharmacodynamic considerations. Clin Pharmacokinet. 1996; 30: 300-13
  CrossrefPubMedGoogle Scholar
• 103 Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res. 1994; 11: 1221-
  CrossrefPubMedGoogle Scholar
• 104 Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry. 2001; 62 (Suppl 5) 4-9
  PubMedGoogle Scholar
• 105 Marzo A, Balant LP. The bioequivalence: an updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneimittelforschung. 1995; 45: 109-15
  PubMedGoogle Scholar
• 106 Amidon GL, Lennemäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12: 413-20
  CrossrefPubMedGoogle Scholar